Advertisement

Topics

IGF Oncology in Phase 1b/2a for its blood cancer treatment at the Mayo Clinic

19:26 EST 8 Jan 2019 | Proactive Investors

IGF Oncology CEO Hugh McTavish sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

IGF Oncology is a biotech company developing targeted anti-cancer drugs. Its lead drug, IGF-MTX, targets blood cancer, and is currently in clinical trials at the Mayo Clinic.

Original Article: IGF Oncology in Phase 1b/2a for its blood cancer treatment at the Mayo Clinic

NEXT ARTICLE

More From BioPortfolio on "IGF Oncology in Phase 1b/2a for its blood cancer treatment at the Mayo Clinic"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...